Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin: 2021-2025

Historic FCF Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 18.29%.

  • Kiniksa Pharmaceuticals International's FCF Margin rose 2030.00% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.03%, marking a year-over-year increase of 1417.00%. This contributed to the annual value of 6.00% for FY2024, which is 113.00% up from last year.
  • Kiniksa Pharmaceuticals International's FCF Margin amounted to 18.29% in Q3 2025, which was up 2.98% from 17.76% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's FCF Margin ranged from a high of 62.57% in Q3 2022 and a low of -236.13% during Q3 2021.
  • Moreover, its 3-year median value for FCF Margin was 5.12% (2023), whereas its average is 8.30%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's FCF Margin spiked by 29,870bps in 2022, and later plummeted by 3,726bps in 2023.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's FCF Margin stood at -102.08% in 2021, then skyrocketed by 10,986bps to 7.78% in 2022, then plummeted by 267bps to 5.12% in 2023, then skyrocketed by 1,014bps to 15.26% in 2024, then surged by 2,030bps to 18.29% in 2025.
  • Its FCF Margin was 18.29% in Q3 2025, compared to 17.76% in Q2 2025 and 16.13% in Q1 2025.